hydrogen sulfide has been researched along with Myocardial Ischemia in 32 studies
Hydrogen Sulfide: A flammable, poisonous gas with a characteristic odor of rotten eggs. It is used in the manufacture of chemicals, in metallurgy, and as an analytical reagent. (From Merck Index, 11th ed)
hydrogen sulfide : A sulfur hydride consisting of a single sulfur atom bonded to two hydrogen atoms. A highly poisonous, flammable gas with a characteristic odour of rotten eggs, it is often produced by bacterial decomposition of organic matter in the absence of oxygen.
thiol : An organosulfur compound in which a thiol group, -SH, is attached to a carbon atom of any aliphatic or aromatic moiety.
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydrogen sulfide (H2S) is an attractive agent for myocardial ischemia-reperfusion injury, however, systemic delivery of H2S may cause unwanted side effects." | 7.83 | Delivery of Hydrogen Sulfide by Ultrasound Targeted Microbubble Destruction Attenuates Myocardial Ischemia-reperfusion Injury. ( Bin, J; Cao, S; Chen, G; Cui, K; Huang, Q; Kutty, S; Liao, W; Liao, Y; Wang, Y; Wu, J; Xiu, J; Yang, L; Zhang, W; Zhong, L, 2016) |
| "To investigate the effect of hydrogen sulfide (H2S) on mitochondrial function in acute myocardial ischemia in rats." | 7.77 | [Effects of hydrogen sulfide on myocardial mitochondrial injury during acute myocardial ischemia in rats]. ( Ding, YY; Li, LF; Liu, F; Zhang, JX; Zhang, QZ; Zhang, XY, 2011) |
| "The role of hydrogen sulfide (H(2)S) in myocardial infarction (MI) has not been previously studied." | 7.74 | Hydrogen sulfide and its possible roles in myocardial ischemia in experimental rats. ( Ho, P; Huang, SH; Loke, YY; Lu, J; Moore, PK; Tan, CS; Wang, ZJ; Whiteman, M; Zhu, YC; Zhu, YZ, 2007) |
| "We investigated whether (endogenous) hydrogen sulfide (H2S) protects the heart against myocardial ischemia and reperfusion injury." | 7.73 | The production of hydrogen sulfide limits myocardial ischemia and reperfusion injury and contributes to the cardioprotective effects of preconditioning with endotoxin, but not ischemia in the rat. ( McDonald, MC; Sivarajah, A; Thiemermann, C, 2006) |
| "Ischemic heart disease is one of the major causes of cardiovascular‑related mortality worldwide." | 6.72 | Cardioprotective effects of hydrogen sulfide in attenuating myocardial ischemia‑reperfusion injury (Review). ( Gu, Y; Wu, D; Zhu, D, 2021) |
| "Hydrogen sulfide (H(2)S) is an endogenous signaling molecule with potent cytoprotective effects." | 5.36 | Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice. ( Calvert, JW; Elrod, JW; Elston, M; Gundewar, S; Jha, S; Lefer, DJ; Nicholson, CK; Ramachandran, A, 2010) |
| "Hydrogen sulfide (H2S) is a gaseous mediator, produced by the metabolic pathways that regulate tissue concentrations of sulfur-containing amino acids." | 5.33 | Exogenous hydrogen sulfide (H2S) protects against regional myocardial ischemia-reperfusion injury--Evidence for a role of K ATP channels. ( Baxter, GF; Johansen, D; Ytrehus, K, 2006) |
| "Hydrogen sulfide (H2S) is an attractive agent for myocardial ischemia-reperfusion injury, however, systemic delivery of H2S may cause unwanted side effects." | 3.83 | Delivery of Hydrogen Sulfide by Ultrasound Targeted Microbubble Destruction Attenuates Myocardial Ischemia-reperfusion Injury. ( Bin, J; Cao, S; Chen, G; Cui, K; Huang, Q; Kutty, S; Liao, W; Liao, Y; Wang, Y; Wu, J; Xiu, J; Yang, L; Zhang, W; Zhong, L, 2016) |
| "Bioavailability of nitric oxide (NO) and hydrogen sulfide (H2S) is reduced in heart failure (HF)." | 3.83 | Nitrite Therapy Ameliorates Myocardial Dysfunction via H2S and Nuclear Factor-Erythroid 2-Related Factor 2 (Nrf2)-Dependent Signaling in Chronic Heart Failure. ( Bhushan, S; Bradley, JM; Donnarumma, E; Donnelly, EL; Islam, KN; Lefer, DJ; Otsuka, H, 2016) |
| "To investigate the effect of hydrogen sulfide (H2S) on mitochondrial function in acute myocardial ischemia in rats." | 3.77 | [Effects of hydrogen sulfide on myocardial mitochondrial injury during acute myocardial ischemia in rats]. ( Ding, YY; Li, LF; Liu, F; Zhang, JX; Zhang, QZ; Zhang, XY, 2011) |
| "In this study, we determined the cardioprotective effects of S-propargyl-cysteine (SPRC), a structural analog of S-allylcysteine (SAC), using in vivo models of acute myocardial infarction (MI) and in vitro hypoxic cardiomyocytes models." | 3.75 | S-propargyl-cysteine protects both adult rat hearts and neonatal cardiomyocytes from ischemia/hypoxia injury: the contribution of the hydrogen sulfide-mediated pathway. ( Liu, HR; Mu, Q; Rose, P; Wang, Q; Zhu, YZ, 2009) |
| "The role of hydrogen sulfide (H(2)S) in myocardial infarction (MI) has not been previously studied." | 3.74 | Hydrogen sulfide and its possible roles in myocardial ischemia in experimental rats. ( Ho, P; Huang, SH; Loke, YY; Lu, J; Moore, PK; Tan, CS; Wang, ZJ; Whiteman, M; Zhu, YC; Zhu, YZ, 2007) |
| "We investigated whether (endogenous) hydrogen sulfide (H2S) protects the heart against myocardial ischemia and reperfusion injury." | 3.73 | The production of hydrogen sulfide limits myocardial ischemia and reperfusion injury and contributes to the cardioprotective effects of preconditioning with endotoxin, but not ischemia in the rat. ( McDonald, MC; Sivarajah, A; Thiemermann, C, 2006) |
| "Ischemic heart disease is one of the major causes of cardiovascular‑related mortality worldwide." | 2.72 | Cardioprotective effects of hydrogen sulfide in attenuating myocardial ischemia‑reperfusion injury (Review). ( Gu, Y; Wu, D; Zhu, D, 2021) |
| "Carbon monoxide (CO) is a gaseous product generated by heme oxygenase (HO), which oxidatively degrades heme." | 2.48 | Carbon monoxide: impact on remethylation/transsulfuration metabolism and its pathophysiologic implications. ( Hishiki, T; Kajimura, M; Kubo, A; Morikawa, T; Suematsu, M; Yamamoto, T, 2012) |
| "Hydrogen sulfide (H2S) is a gaseous signaling molecule that regulates cardiovascular function." | 1.42 | miRNA-30 family inhibition protects against cardiac ischemic injury by regulating cystathionine-γ-lyase expression. ( Guo, W; Lin, S; Miao, L; Shen, Y; Shen, Z; Xin, X; Zhu, Y; Zhu, YZ, 2015) |
| "Hydrogen sulfide (H( 2)S) is a biological mediator produced by enzyme-regulated pathways from L-cysteine, which is a substrate for cystathionine-gamma-lyase (CSE)." | 1.36 | L-cysteine stimulates hydrogen sulfide synthesis in myocardium associated with attenuation of ischemia-reperfusion injury. ( Baxter, GF; Elsey, DJ; Fowkes, RC, 2010) |
| "Hydrogen sulfide (H(2)S) is an endogenous signaling molecule with potent cytoprotective effects." | 1.36 | Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice. ( Calvert, JW; Elrod, JW; Elston, M; Gundewar, S; Jha, S; Lefer, DJ; Nicholson, CK; Ramachandran, A, 2010) |
| "Hydrogen sulfide (H2S) is a gaseous mediator, produced by the metabolic pathways that regulate tissue concentrations of sulfur-containing amino acids." | 1.33 | Exogenous hydrogen sulfide (H2S) protects against regional myocardial ischemia-reperfusion injury--Evidence for a role of K ATP channels. ( Baxter, GF; Johansen, D; Ytrehus, K, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (15.63) | 29.6817 |
| 2010's | 25 (78.13) | 24.3611 |
| 2020's | 2 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, D | 1 |
| Gu, Y | 1 |
| Zhu, D | 1 |
| Hsieh, MH | 1 |
| Tsai, HW | 1 |
| Lin, KJ | 1 |
| Wu, ZY | 1 |
| Hu, HY | 1 |
| Chang, Y | 1 |
| Wei, HJ | 1 |
| Sung, HW | 1 |
| Chen, Y | 2 |
| Zhang, F | 1 |
| Yin, J | 1 |
| Wu, S | 1 |
| Zhou, X | 1 |
| Takatani-Nakase, T | 1 |
| Katayama, M | 1 |
| Matsui, C | 1 |
| Hanaoka, K | 1 |
| van der Vlies, AJ | 1 |
| Takahashi, K | 1 |
| Nakase, I | 1 |
| Hasegawa, U | 1 |
| Bai, YD | 2 |
| Yang, YR | 1 |
| Mu, XP | 1 |
| Lin, G | 1 |
| Wang, YP | 1 |
| Jin, S | 2 |
| Wang, MJ | 2 |
| Zhu, YC | 3 |
| Wang, W | 1 |
| Liu, H | 1 |
| Lu, Y | 1 |
| Wang, X | 1 |
| Zhang, B | 1 |
| Cong, S | 1 |
| Zhao, Y | 3 |
| Ji, M | 1 |
| Tao, H | 1 |
| Wei, L | 1 |
| Casalini, ED | 1 |
| Goodwill, AG | 1 |
| Owen, MK | 1 |
| Moberly, SP | 1 |
| Berwick, ZC | 1 |
| Tune, JD | 1 |
| Kan, J | 1 |
| Guo, W | 2 |
| Huang, C | 1 |
| Bao, G | 1 |
| Zhu, Y | 2 |
| Zhu, YZ | 6 |
| Zhang, Y | 1 |
| Li, H | 3 |
| Zhao, G | 1 |
| Sun, A | 1 |
| Zong, NC | 1 |
| Li, Z | 1 |
| Zhu, H | 1 |
| Zou, Y | 1 |
| Yang, X | 1 |
| Ge, J | 1 |
| Toldo, S | 1 |
| Das, A | 1 |
| Mezzaroma, E | 1 |
| Chau, VQ | 1 |
| Marchetti, C | 1 |
| Durrant, D | 1 |
| Samidurai, A | 1 |
| Van Tassell, BW | 1 |
| Yin, C | 1 |
| Ockaili, RA | 1 |
| Vigneshwar, N | 1 |
| Mukhopadhyay, ND | 1 |
| Kukreja, RC | 1 |
| Abbate, A | 1 |
| Salloum, FN | 1 |
| Dudek, M | 1 |
| Knutelska, J | 1 |
| Bednarski, M | 1 |
| Nowiński, L | 1 |
| Zygmunt, M | 1 |
| Bilska-Wilkosz, A | 1 |
| Iciek, M | 1 |
| Otto, M | 1 |
| Żytka, I | 1 |
| Sapa, J | 1 |
| Włodek, L | 1 |
| Filipek, B | 1 |
| Andreadou, I | 2 |
| Iliodromitis, EK | 2 |
| Rassaf, T | 1 |
| Schulz, R | 1 |
| Papapetropoulos, A | 2 |
| Ferdinandy, P | 1 |
| Shen, Y | 1 |
| Shen, Z | 1 |
| Miao, L | 1 |
| Xin, X | 1 |
| Lin, S | 1 |
| Penna, C | 1 |
| Granata, R | 1 |
| Tocchetti, CG | 1 |
| Gallo, MP | 1 |
| Alloatti, G | 1 |
| Pagliaro, P | 1 |
| Wei, C | 1 |
| Wang, L | 1 |
| Peng, X | 1 |
| He, Y | 1 |
| Shao, H | 1 |
| Zhong, X | 1 |
| Xu, C | 1 |
| Wen, YD | 1 |
| Lougiakis, N | 1 |
| Gikas, E | 1 |
| Toumpas, S | 1 |
| Efentakis, P | 1 |
| Wedmann, R | 1 |
| Zoga, A | 1 |
| Zhou, Z | 1 |
| Skaltsounis, AL | 1 |
| Filipovic, MR | 1 |
| Pouli, N | 1 |
| Marakos, P | 1 |
| Shimizu, Y | 1 |
| Nicholson, CK | 2 |
| Lambert, JP | 1 |
| Barr, LA | 1 |
| Kuek, N | 1 |
| Herszenhaut, D | 1 |
| Tan, L | 1 |
| Murohara, T | 1 |
| Hansen, JM | 1 |
| Husain, A | 1 |
| Naqvi, N | 1 |
| Calvert, JW | 2 |
| Li, N | 1 |
| Hou, CL | 1 |
| Ma, FF | 1 |
| Li, XH | 1 |
| Wang, J | 1 |
| Hu, X | 1 |
| Jiang, H | 1 |
| Chen, G | 1 |
| Yang, L | 1 |
| Zhong, L | 1 |
| Kutty, S | 1 |
| Wang, Y | 1 |
| Cui, K | 1 |
| Xiu, J | 1 |
| Cao, S | 1 |
| Huang, Q | 1 |
| Liao, W | 1 |
| Liao, Y | 1 |
| Wu, J | 1 |
| Zhang, W | 1 |
| Bin, J | 1 |
| Donnarumma, E | 1 |
| Bhushan, S | 1 |
| Bradley, JM | 1 |
| Otsuka, H | 1 |
| Donnelly, EL | 1 |
| Lefer, DJ | 2 |
| Islam, KN | 1 |
| Wang, Q | 2 |
| Liu, HR | 2 |
| Mu, Q | 1 |
| Rose, P | 2 |
| Wang, XL | 1 |
| Elsey, DJ | 1 |
| Fowkes, RC | 1 |
| Baxter, GF | 2 |
| Elston, M | 1 |
| Gundewar, S | 1 |
| Jha, S | 1 |
| Elrod, JW | 1 |
| Ramachandran, A | 1 |
| Liu, F | 1 |
| Zhang, JX | 1 |
| Li, LF | 1 |
| Zhang, QZ | 1 |
| Ding, YY | 1 |
| Zhang, XY | 1 |
| Hishiki, T | 1 |
| Yamamoto, T | 1 |
| Morikawa, T | 1 |
| Kubo, A | 1 |
| Kajimura, M | 1 |
| Suematsu, M | 1 |
| Geng, B | 1 |
| Chang, L | 1 |
| Pan, C | 1 |
| Qi, Y | 1 |
| Zhao, J | 1 |
| Pang, Y | 1 |
| Du, J | 1 |
| Tang, C | 1 |
| Johansen, D | 1 |
| Ytrehus, K | 1 |
| Sivarajah, A | 1 |
| McDonald, MC | 1 |
| Thiemermann, C | 1 |
| Wang, ZJ | 1 |
| Ho, P | 1 |
| Loke, YY | 1 |
| Huang, SH | 1 |
| Tan, CS | 1 |
| Whiteman, M | 1 |
| Lu, J | 1 |
| Moore, PK | 1 |
6 reviews available for hydrogen sulfide and Myocardial Ischemia
| Article | Year |
|---|---|
Cardioprotective effects of hydrogen sulfide in attenuating myocardial ischemia‑reperfusion injury (Review).
Topics: Animals; Cardiotonic Agents; Heart; Humans; Hydrogen Sulfide; Ischemic Postconditioning; Myocardial | 2021 |
Protective mechanisms of hydrogen sulfide in myocardial ischemia.
Topics: Animals; Cardiovascular Diseases; Cystathionine gamma-Lyase; Humans; Hydrogen Sulfide; Mitochondria; | 2020 |
The role of gasotransmitters NO, H2S and CO in myocardial ischaemia/reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning.
Topics: Animals; Cardiotonic Agents; Gasotransmitters; Humans; Hydrogen Sulfide; Ischemic Postconditioning; | 2015 |
Endogenous Cardioprotective Agents: Role in Pre and Postconditioning.
Topics: Animals; Carbon Monoxide; Cardiotonic Agents; Gasotransmitters; Humans; Hydrogen Sulfide; Ischemic P | 2015 |
The Pharmacological Effects of S-Propargyl-Cysteine, a Novel Endogenous H2S-Producing Compound.
Topics: Animals; Chemistry, Pharmaceutical; Cysteine; Heart Failure; Humans; Hydrogen Sulfide; Myocardial Is | 2015 |
Carbon monoxide: impact on remethylation/transsulfuration metabolism and its pathophysiologic implications.
Topics: Carbon Monoxide; Cystathionine beta-Synthase; Heme Oxygenase (Decyclizing); Humans; Hydrogen Sulfide | 2012 |
26 other studies available for hydrogen sulfide and Myocardial Ischemia
| Article | Year |
|---|---|
An in situ slow-releasing H
Topics: Allyl Compounds; Animals; Antioxidants; Apoptosis; Cardiotonic Agents; Cell Line; Delayed-Action Pre | 2019 |
Hydrogen sulfide donor micelles protect cardiomyocytes from ischemic cell death.
Topics: Animals; Cell Death; Cell Survival; Cells, Cultured; Humans; Hydrogen Sulfide; Micelles; Myocardial | 2017 |
Hydrogen Sulfide Alleviates Acute Myocardial Ischemia Injury by Modulating Autophagy and Inflammation Response under Oxidative Stress.
Topics: Acute Disease; Animals; Hydrogen Sulfide; Male; Mice; Mice, Knockout; Myocardial Ischemia; Oxidative | 2018 |
Controlled-releasing hydrogen sulfide donor based on dual-modal iron oxide nanoparticles protects myocardial tissue from ischemia-reperfusion injury.
Topics: Allyl Compounds; Animals; Cardiotonic Agents; Cell Line; Delayed-Action Preparations; Ferric Compoun | 2019 |
Contribution of hydrogen sulfide to the control of coronary blood flow.
Topics: Animals; Blood Flow Velocity; Coronary Circulation; Dogs; Female; Gasotransmitters; Hydrogen Sulfide | 2014 |
S-propargyl-cysteine, a novel water-soluble modulator of endogenous hydrogen sulfide, promotes angiogenesis through activation of signal transducer and activator of transcription 3.
Topics: Active Transport, Cell Nucleus; Angiogenesis Inducing Agents; Animals; Cell Adhesion; Cell Movement; | 2014 |
Hydrogen sulfide attenuates the recruitment of CD11b⁺Gr-1⁺ myeloid cells and regulates Bax/Bcl-2 signaling in myocardial ischemia injury.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; bcl-2-Associated X Protein; CD11b Antigen; Cell Moveme | 2014 |
Induction of microRNA-21 with exogenous hydrogen sulfide attenuates myocardial ischemic and inflammatory injury in mice.
Topics: Animals; Cells, Cultured; Humans; Hydrogen Sulfide; Male; Mice; Mice, Inbred C57BL; MicroRNAs; Myoca | 2014 |
Alpha lipoic acid protects the heart against myocardial post ischemia-reperfusion arrhythmias via KATP channel activation in isolated rat hearts.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Animals; Antioxidants; Arrhythmias, C | 2014 |
miRNA-30 family inhibition protects against cardiac ischemic injury by regulating cystathionine-γ-lyase expression.
Topics: Animals; Base Sequence; Binding Sites; Cystathionine gamma-Lyase; Enzyme Repression; HEK293 Cells; H | 2015 |
H2 S restores the cardioprotection from ischemic post-conditioning in isolated aged rat hearts.
Topics: Aging; Animals; Cardiotonic Agents; Heart; Hydrogen Sulfide; Ischemic Postconditioning; Myocardial I | 2015 |
Synthesis and Pharmacological Evaluation of Novel Adenine-Hydrogen Sulfide Slow Release Hybrids Designed as Multitarget Cardioprotective Agents.
Topics: Adenine; Animals; Blood Pressure; Cardiotonic Agents; Drug Design; Heart Rate; Hydrogen Sulfide; Mal | 2016 |
Sodium Sulfide Attenuates Ischemic-Induced Heart Failure by Enhancing Proteasomal Function in an Nrf2-Dependent Manner.
Topics: Animals; Cardiovascular Agents; Disease Models, Animal; Endoplasmic Reticulum Stress; Heart Failure; | 2016 |
The H2S Donor NaHS Changes the Expression Pattern of H2S-Producing Enzymes after Myocardial Infarction.
Topics: Animals; Cell Hypoxia; Cystathionine beta-Synthase; Cystathionine gamma-Lyase; Cytoprotection; Hydro | 2016 |
ER stress-induced apoptosis: A novel therapeutic target in myocardial ischemia and reperfusion injury.
Topics: Apoptosis; Endoplasmic Reticulum Stress; Humans; Hydrogen Sulfide; Myocardial Ischemia; Myocardial R | 2016 |
Delivery of Hydrogen Sulfide by Ultrasound Targeted Microbubble Destruction Attenuates Myocardial Ischemia-reperfusion Injury.
Topics: Animals; Disease Models, Animal; Drug Delivery Systems; Hydrogen Sulfide; Lung; Microbubbles; Myocar | 2016 |
Nitrite Therapy Ameliorates Myocardial Dysfunction via H2S and Nuclear Factor-Erythroid 2-Related Factor 2 (Nrf2)-Dependent Signaling in Chronic Heart Failure.
Topics: Animals; Antioxidants; Cardiotonic Agents; Coronary Occlusion; Heart Failure; Hydrogen Sulfide; Male | 2016 |
S-propargyl-cysteine protects both adult rat hearts and neonatal cardiomyocytes from ischemia/hypoxia injury: the contribution of the hydrogen sulfide-mediated pathway.
Topics: Animals; Animals, Newborn; Cell Hypoxia; Cell Survival; Cystathionine gamma-Lyase; Cysteine; Disease | 2009 |
Protective effects of cysteine analogues on acute myocardial ischemia: novel modulators of endogenous H(2)S production.
Topics: Air Pollutants; Animals; Antioxidants; Cardiotonic Agents; Catalase; Cysteine; Glutathione Peroxidas | 2010 |
L-cysteine stimulates hydrogen sulfide synthesis in myocardium associated with attenuation of ischemia-reperfusion injury.
Topics: Alkynes; Analysis of Variance; Animals; Cysteine; Disease Models, Animal; Drug Therapy, Combination; | 2010 |
Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice.
Topics: Animals; Body Weight; Cardiomegaly; Cystathionine gamma-Lyase; Gene Expression Regulation, Enzymolog | 2010 |
[Effects of hydrogen sulfide on myocardial mitochondrial injury during acute myocardial ischemia in rats].
Topics: Adenosine Triphosphatases; Animals; Glutathione Peroxidase; Hydrogen Sulfide; Lipid Peroxidation; Ma | 2011 |
Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol.
Topics: Alkenes; Animals; Carbon-Oxygen Lyases; Cardiotonic Agents; Creatine Kinase; Free Radical Scavengers | 2004 |
Exogenous hydrogen sulfide (H2S) protects against regional myocardial ischemia-reperfusion injury--Evidence for a role of K ATP channels.
Topics: Adenosine Triphosphate; Animals; Anti-Arrhythmia Agents; Cardiac Output; Decanoic Acids; Glyburide; | 2006 |
The production of hydrogen sulfide limits myocardial ischemia and reperfusion injury and contributes to the cardioprotective effects of preconditioning with endotoxin, but not ischemia in the rat.
Topics: Alkynes; Animals; Cardiotonic Agents; Cystathionine gamma-Lyase; Decanoic Acids; Endotoxins; Enzyme | 2006 |
Hydrogen sulfide and its possible roles in myocardial ischemia in experimental rats.
Topics: Alkynes; Animals; Cell Death; Cells, Cultured; Culture Media; Cystathionine gamma-Lyase; Disease Mod | 2007 |